Kojin Therapeutics has raised $60 million to use iron-dependent cell death to treat drug-resistant cancer. The series A round positions the biotech to build on the work its scientific founders did at institutions including Harvard University and Dana-Farber Cancer Institute.
Published: Jun 09, 2021 By Mark Terry
Kojin Therapeutics
launched with a $60 million Series A to initially focus on oncology and cell state biology. The round was led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital. Participants included Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.
The approach came out of the
laboratoryof Stuart Schreiber, Harvard University professor and co-founder of the Broad Institute. Co-founders of Kojin include Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan. The company’s technology is ferroptosis-based drug discovery, which is to say, iron-dependent cell death. Kojin says that difficult-to-treat diseases, which includes drug-resistant cancers, involve diseased cells that are sensitive to ferroptosis.
Dr Fauci briefed world leaders that coronavirus could have escaped from Wuhan lab in SPRING, Former FDA commissioner Scott Gottlieb reveals, despite his public insistence it came from a bat
Former FDA Commissioner Scott Gottlieb said he was told Dr. Fauci had briefed world leaders on the possibility that the novel coronavirus leaked from a lab
Gottlieb said a senior Trump official pointed to suspicions the strain looked unusual, prompting Fauci to address the possibility that it had leaked from a lab
Gottlieb defended Fauci by highlighting the point the virus originated one of two ways: Either occurring in nature such as from a bat, or man made in a laboratory
WASHINGTON, June 7 In the four decades since the first cases of what would come to be known as AIDS were documented, scientists have made huge strides in HIV treatment, transforming what was once a death sentence to a manageable condition. What we still don’t have is a vaccine that would.